ATE451103T1 - Zusammensetzung zur behandlung von atherosklerose,die candesartan und rosuvastatin enthält - Google Patents

Zusammensetzung zur behandlung von atherosklerose,die candesartan und rosuvastatin enthält

Info

Publication number
ATE451103T1
ATE451103T1 AT04768663T AT04768663T ATE451103T1 AT E451103 T1 ATE451103 T1 AT E451103T1 AT 04768663 T AT04768663 T AT 04768663T AT 04768663 T AT04768663 T AT 04768663T AT E451103 T1 ATE451103 T1 AT E451103T1
Authority
AT
Austria
Prior art keywords
rosuvastatin
treatment
composition
containing candesartan
atherosclerosis containing
Prior art date
Application number
AT04768663T
Other languages
English (en)
Inventor
Jay Mehta
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Application granted granted Critical
Publication of ATE451103T1 publication Critical patent/ATE451103T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Materials For Medical Uses (AREA)
AT04768663T 2003-09-26 2004-09-22 Zusammensetzung zur behandlung von atherosklerose,die candesartan und rosuvastatin enthält ATE451103T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0322552.1A GB0322552D0 (en) 2003-09-26 2003-09-26 Therapeutic treatment
PCT/GB2004/004120 WO2005030215A2 (en) 2003-09-26 2004-09-22 Therapeutic treatment

Publications (1)

Publication Number Publication Date
ATE451103T1 true ATE451103T1 (de) 2009-12-15

Family

ID=29286881

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04768663T ATE451103T1 (de) 2003-09-26 2004-09-22 Zusammensetzung zur behandlung von atherosklerose,die candesartan und rosuvastatin enthält

Country Status (28)

Country Link
US (2) US7932263B2 (de)
EP (1) EP1673091B1 (de)
JP (1) JP4841433B2 (de)
KR (1) KR101129767B1 (de)
CN (1) CN100515421C (de)
AT (1) ATE451103T1 (de)
AU (1) AU2004275567B2 (de)
BR (1) BRPI0414724A (de)
CA (1) CA2540102C (de)
CY (1) CY1109814T1 (de)
DE (1) DE602004024555D1 (de)
DK (1) DK1673091T3 (de)
ES (1) ES2336450T3 (de)
GB (1) GB0322552D0 (de)
HR (1) HRP20100080T1 (de)
IL (1) IL174536A (de)
IS (1) IS2729B (de)
MX (1) MXPA06003353A (de)
NO (1) NO335813B1 (de)
NZ (1) NZ546162A (de)
PL (1) PL1673091T3 (de)
PT (1) PT1673091E (de)
RU (1) RU2358737C2 (de)
SG (1) SG145773A1 (de)
SI (1) SI1673091T1 (de)
UA (1) UA90249C2 (de)
WO (1) WO2005030215A2 (de)
ZA (1) ZA200602433B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
WO2007051007A2 (en) * 2005-10-28 2007-05-03 Novartis Ag Combination of antihypertensives with cholesterol-lowering agent
EP2483401B1 (de) * 2009-09-29 2017-06-21 Butamax (TM) Advanced Biofuels LLC Wirtszellen mit erhöhter hefeproduktion
US20120239131A1 (en) * 2011-03-15 2012-09-20 Medtronic Vascular, Inc. Methods and apparatus for treatment of aneurysmal tissue
US9498464B2 (en) * 2011-12-09 2016-11-22 Artskin D.O.O. Treatment of arterial wall by combination of RAAS inhibitor and HMG-CoA reductase inhibitor
CN103479627A (zh) * 2013-05-16 2014-01-01 武汉光谷百桥国际生物科技有限公司 一种血管紧张素ii的i型受体拮抗剂在促进毛发生长方面的应用
KR101771766B1 (ko) 2013-12-30 2017-08-28 알보젠코리아 주식회사 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제
BR112019009709A2 (pt) * 2016-11-15 2019-08-13 Lg Chemical Ltd preparação de combinação.

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US6004989A (en) 1990-04-27 1999-12-21 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US5703110A (en) 1990-04-27 1997-12-30 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5721263A (en) 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
CA2125251C (en) 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
CA2186606A1 (en) 1994-03-29 1995-10-05 Edward B. Nelson Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
FR2741620B1 (fr) 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
EP0914158B2 (de) 1996-04-05 2006-01-25 Takeda Chemical Industries, Ltd. Pharmazeutische kombination enthaltend einen wirkstoff mit angiotensin-ii antagonistischer aktivität und einen wirkstoff der die insulin-sensitivität erhöht
DE69731840T2 (de) * 1996-07-15 2005-08-04 Sankyo Co., Ltd. Pharmazeutische Zusammensetzungen enthaltend CS-866 und Insulinresistenz verbessernde Mittel und deren Verwendung zur Behandlung von Arteriosklerose und Xanthom
JPH1081633A (ja) 1996-07-16 1998-03-31 Sankyo Co Ltd 医薬組成物
AP1207A (en) 1997-08-29 2003-09-20 Pfizer Prod Inc Combination therapy.
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
GB9900339D0 (en) 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
AR022462A1 (es) 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
GB0000710D0 (en) 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
GB9903472D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7125883B1 (en) 1999-04-13 2006-10-24 Abbott Gmbh & Co. Kg Integrin receptor ligands
DK1216038T3 (da) 1999-08-30 2005-12-27 Sanofi Aventis Deutschland Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
EP1212101A1 (de) 1999-08-31 2002-06-12 The Brigham And Women's Hospital, Inc. Systemische entzündungsmarker als diagnostisches werkzeug um arteriosklerotische erkrankungen zu verhindern
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
AU2000254249A1 (en) 2000-03-28 2001-10-08 Biocon India Limited Synthesis of (r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-
AR030414A1 (es) 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
CN1440283A (zh) * 2000-04-12 2003-09-03 诺瓦提斯公司 有机化合物的联合形式
US6620821B2 (en) * 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
AU2001284413A1 (en) * 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
JP2002145770A (ja) * 2000-08-30 2002-05-22 Sankyo Co Ltd 心不全の予防又は治療のための医薬組成物
GB0028429D0 (en) 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
IL156585A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
DK1355644T3 (da) * 2001-01-26 2006-10-23 Schering Corp Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
WO2002095402A2 (en) * 2001-04-18 2002-11-28 Mcgill University Individualization of therapy with hyperlipidemia agents
SE0103509D0 (sv) 2001-10-19 2001-10-19 Astrazeneca Ab Rosuvastatin in pre demented states
OA13050A (en) * 2003-04-29 2006-11-10 Pfizer Ltd 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
JP2005126338A (ja) 2003-10-21 2005-05-19 Boehringer Ingelheim Pharma Gmbh & Co Kg 心不全治療剤
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
US20060078615A1 (en) 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin

Also Published As

Publication number Publication date
HK1090553A1 (en) 2006-12-29
RU2006113366A (ru) 2007-11-10
NO335813B1 (no) 2015-02-23
US20070275989A1 (en) 2007-11-29
JP4841433B2 (ja) 2011-12-21
AU2004275567B2 (en) 2008-01-10
WO2005030215A3 (en) 2005-06-02
SG145773A1 (en) 2008-09-29
MXPA06003353A (es) 2006-06-08
EP1673091A2 (de) 2006-06-28
CA2540102C (en) 2012-07-24
ES2336450T3 (es) 2010-04-13
IL174536A (en) 2010-12-30
EP1673091B1 (de) 2009-12-09
JP2007506720A (ja) 2007-03-22
DE602004024555D1 (de) 2010-01-21
US20110046119A1 (en) 2011-02-24
NZ546162A (en) 2008-11-28
CN100515421C (zh) 2009-07-22
KR101129767B1 (ko) 2012-03-26
DK1673091T3 (da) 2010-03-22
NO20061744L (no) 2006-06-22
CA2540102A1 (en) 2005-04-07
HRP20100080T1 (hr) 2010-04-30
KR20060108623A (ko) 2006-10-18
AU2004275567A1 (en) 2005-04-07
IL174536A0 (en) 2008-04-13
SI1673091T1 (sl) 2010-03-31
CY1109814T1 (el) 2014-09-10
IS2729B (is) 2011-04-15
US7932263B2 (en) 2011-04-26
UA90249C2 (uk) 2010-04-26
ZA200602433B (en) 2007-06-27
WO2005030215A2 (en) 2005-04-07
RU2358737C2 (ru) 2009-06-20
IS8421A (is) 2006-04-21
PT1673091E (pt) 2010-02-15
GB0322552D0 (en) 2003-10-29
CN1886136A (zh) 2006-12-27
BRPI0414724A (pt) 2006-11-21
PL1673091T3 (pl) 2010-04-30

Similar Documents

Publication Publication Date Title
CY1109814T1 (el) Ενας συνδυασμος που περιεχει candesartan και rosuvastatin για τη θεραπευτικη αντιμετωπιση της αρτηριοσκληρυνσης
DE60137329D1 (de) Zusammensetzungen zur behandlung von diabetes die einen dp iv-inhibitoren und einen andere antidiabetikum enthalten
ATE368031T1 (de) Neue gamma secretase inhibitoren
DE60329533D1 (de) Cyclische sulfamide zur inhibierung von gamma-sekretase
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
DE50214540D1 (de) Stanz bei der behandlung von wunden
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
ATE414089T1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
IS7721A (is) Píperidín-pýrídasón og þalasón sem PDE4 hemlar
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
DE60221627D1 (de) Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren
WO2004018431A3 (en) Novel phenanthridines
DE60133921D1 (de) Verwendung von rosuvastatin (zd-4522) zur behandlung von heterozygoter familiärer hypercholesterolämie
DE69939481D1 (de) Methode zur behandlung von diabetes die einen ap2-inhibitor und dazugehörige kombinationen verwendet
DE60208186D1 (de) Chinazolin- und chinazolinähnliche verbindungen zur behandlung von integrinvermittelten erkrankungen
DE60236218D1 (de) CCR5 Antagonisten verwendbar für die Behandlung von Aids
DE60139466D1 (de) Behandlung von diabetes
DE60134009D1 (de) Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose
DE602004022153D1 (de) Verbindungen zur behandlung von obesitas
ATE469886T1 (de) 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen
ATE422201T1 (de) 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
ATE502631T1 (de) Verbindungen zur behandlung von stoffwechselstörungen
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE60032777D1 (de) Zusammensetzung zur behandlung von virusinfektionen, die einen calcium-kanal-blocker und ein chinolin enthält
DE50302552D1 (de) Verwendung von treosulfan und derivaten davon zur behandlung der multiplen sklerose

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1673091

Country of ref document: EP